Methods of treating psoriasis using IL-17 antagonists
AssigneeNovartis AG
InventorsAchim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
Life of this patent
Estimating the term…
Abstract
The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
Claims37
A method of treating psoriasis, comprising subcutaneously administering to a patient in need thereof a dose of about 150 mg-about 300 mg of an IL-17 antibody weekly during week 0, 1, 2, 3, and 4, and then bimonthly (twice a month) thereafter, wherein the IL-17 antibody comprises:
- i) an immunoglobulin heavy chain variable (VH) domain comprising the amino acid sequence set forth as SEQ ID NO:8, and an immunoglobulin light chain variable (VL) domain comprising the amino acid sequence set forth as SEQ ID NO:10;
- ii) an immunoglobulin VH domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively;
- and an immunoglobulin VL domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, respectively;
- or
- iii) an immunoglobulin VH domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13, respectively;
- and an immunoglobulin VL domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, respectively.
A method of treating psoriasis, comprising subcutaneously administering to a patient in need thereof a dose of about 150 mg or about 300 mg secukinumab during week 0, 1, 2, 3, and 4, followed by a dose of about 150 mg or about 300 mg secukinumab during a maintenance regimen, wherein the maintenance regimen comprises administering secukinumab to the patient every four weeks if the patient is a responder to treatment with secukinumab or bimonthly (twice a month) if the patient is a partial responder or a non-responder to treatment with secukinumab.
A method of treating psoriasis, comprising subcutaneously administering to a patient in need thereof a dose of about 150 mg or 300 mg secukinumab during week 0, 1, 2, 3, and 4, and then bimonthly (twice a month) thereafter.
Dependencies are inferred from the claim text.